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Abstract
Background
The burden of diabetes is increasing in sub-Saharan Africa, including among people living
with HIV. We assessed the prevalence of diabetes and the roles of HIV, antiretroviral ther-
apy (ART) and traditional risk factors among adults in Tanzania.
Methods
We analysed diabetes-relevant baseline data from 1,947 adult participants in the CICADA
study in Mwanza, Tanzania: 655 HIV-uninfected, 956 HIV-infected ART-naïve, and 336
HIV-infected persons on ART. WHO guidelines for haemoglobin A1c (HbA1c) and oral glu-
cose tolerance test (OGTT) were used to define diabetes and prediabetes. Risk factors
were evaluated using multinomial logistic regression analysis. Relative risk ratios (RRR)
were generated comparing participants with diabetes and prediabetes against the reference
of those with no diabetes.
Results
Mean age was 41 (SD 12) years; 59% were women. The prevalence of diabetes was 13%
by HbA1c and 6% by OGTT, with partial overlap among participants identified by the two
tests. Relative to HIV-uninfected, HIV-infected ART-naïve persons had increased relative
risks of diabetes (HbA1c: RRR = 1.95, 95% CI 1.25–3.03; OGTT: RRR = 1.90, 95% CI
0.96–3.73) and prediabetes (HbA1c: RRR = 2.89, 95% CI 1.93–4.34; OGTT: RRR = 1.61,
95% CI 1.22–2.13). HIV-infected participants on ART showed increased risk of prediabetes
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(RRR 1.80, 95% CI 1.09, 2.94) by HbA1c, but not diabetes. CD4 count < 200 cell/μL at
recruitment increased risk and physical activity decreased risk of diabetes by both HbA1c
and OGTT.
Conclusions
The prevalence of diabetes was high, especially among HIV-infected ART-naïve adults.
Being more physically active was associated with lower risk of diabetes. HbA1c and OGTT
identified different participants as having diabetes or prediabetes. Overall, the finding of
high burden of diabetes among HIV-infected persons suggests that health systems should
consider integrating diabetes screening and treatment in HIV clinics to optimize the care of
HIV patients and improve their health outcomes.
Introduction
Diabetes mellitus is an emerging public health problem in sub-Saharan Africa (SSA) [1, 2], due
to the nutrition transition and globalization [1, 3]. Increasing overall life expectancy in SSA
further increases the risk of diabetes [4]. Compared to people from high-income countries,
inhabitants of SSA seem to be at risk of diabetes at younger age and may have different risk fac-
tors including HIV infection [3, 5, 6]. Scarce data from SSA [7] limits health system responses
to non-communicable diseases (NCDs) including diabetes [2].
Most research on diabetes in HIV-infected individuals has been done in high-income coun-
tries where data suggest that, although antiretroviral therapy (ART) can suppress viral load,
the health of HIV-infected people is not completely restored, and people living with HIV have
higher risk of diabetes than HIV-uninfected [8]. Studies investigating the mechanisms of glu-
cose dysregulation among HIV-infected persons have been conflicting, but they mainly sug-
gest that higher risk is related to HIV infection, co-morbidities, micronutrient deficiencies,
specific antiretroviral drugs, individual genetic susceptibility or combinations of these factors
[9, 10]. HIV infection triggers immune activation and chronic inflammation, which persist
even after ART initiation, and this may lead to diabetes [11, 12]. During early HIV recovery in
malnourished patients, rapid regain of fat rather than lean mass may occur [13], and could
potentially increase the risk of diabetes. Although HIV and ART may have similar effects on
diabetes in SSA as in high-income countries, such data cannot be directly extrapolated to SSA
because of differing risk factors such as a lower prevalence of obesity, history of nutritional
deficiencies, higher exposure to infections, and use of older antiretroviral drugs which have
been associated with excess diabetes risk [14–17]. We therefore conducted a study to investi-
gate the prevalence of diabetes and to assess the roles of HIV infection, ART and traditional
risk factors.
Methods
Study design and setting
This was a cross-sectional study using baseline data (October 2016 to November 2017) from
adults (age�18 years) enrolled in the Diabetes and Associated Complications in HIV Patients
study which is locally called Chronic Infections, Co-morbidities and Diabetes in Africa
(CICADA), a cohort study investigating the burden of and risk factors for diabetes in Mwanza,
Tanzania, registered at https://clinicaltrials.gov as NCT03106480.
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Participant eligibility
Three cohorts were invited to join CICADA: (1) participants in Nutrition, Diabetes and Pul-
monary Tuberculosis (TB-NUT), registered at https://clinicaltrials.gov/ as NCT00311298,
conducted from 2006 to 2009. [6, 18–20]; (2) participants in Nutritional Support for African
Adults Starting Antiretroviral Therapy (NUSTART), conducted from August 2011 to Decem-
ber 2013 [21], registered at the Pan African Clinical Trial registry as PACTR201106000300631;
and (3) a new cohort comprising newly diagnosed HIV-infected, ART-naïve participants from
ART clinics in Mwanza and HIV-uninfected controls from the neighbourhoods of new HIV
cohort participants. The overall CICADA cohort thus comprised HIV-infected individuals on
ART as well as HIV-infected ART-naïve individuals and HIV-uninfected controls.
Recruitment of participants from previous cohorts
All participants who were known to be alive at the end of the follow-up in the previous cohorts
(TB-NUT and NUSTART) were telephoned and introduced to the CICADA study. If partici-
pants were interested an appointment was scheduled. Participants who were not reachable by
phone were visited at home and invited to join the study. If they were still not reachable, people
responding to the phone call or those found in participants’ homes were requested to provide
information on participants’ vital status and if they had travelled temporarily or relocated per-
manently from Mwanza. Eligible persons were requested to come to the research clinic in
Mwanza at 8:00 am after an overnight fast of at least 8 hours to receive further study informa-
tion, for consenting and for study procedures.
Recruitment of new HIV-infected participants and HIV-negative controls
HIV-infected people who visited ART clinics in Mwanza City and were preparing to start ART
were provided information about the study and asked to come to the study clinic for enrol-
ment if they were aged 18 years and above, residents of Mwanza City, willing to consent and
intending to remain in the area for the next three years. Using a computer-generated randomi-
zation list, we randomly took half of the new HIV-infected participants and selected HIV-
uninfected participants for frequency matching. Criteria for HIV-negative participants were:
lived within the same neighbourhood as the HIV index participant (defined as living in the
same street or sub-village), HIV-negative based on HIV rapid tests, had lived in Mwanza City
for at least 3 months with no plans for relocating within the next 3 years, aged 18 years or
above and age difference with HIV-infected index participant not more than 5 years, same sex
as the HIV-infected index participant, and willing to consent. Local street leaders of selected
index case were requested to provide a list of households in their street, then 3 households
were randomly chosen for eligibility criteria. If no one in these households met the criteria the
process was repeated until a suitable household was found.
Questionnaire data
Data were collected using structured interviews. Information was gathered on demography,
education, occupation, religion, marital status and, using WHO STEPS questionnaire and
show cards [22], on level of physical activity and alcohol use. For alcohol intake, we also used
previously developed coloured show cards of commonly available alcoholic drinks in Mwanza
[23], with their equivalent standard drink conversions. Information on history of ART use,
adherence, smoking, TB treatment, and symptoms of diabetes were also collected. ART history
was verified through participants’ ART cards or clinic records and grouped based on regimens
containing zidovudine (AZT), abacavir (ABC), or tenofovir (TDF) because of indication of
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these drugs to have effect on glucose tolerance [24]. Total physical activity in metabolic equiva-
lents in minutes per week (MET- minutes) was computed from the STEPS questionnaire and
categorized as<600 or� 600 MET-minutes based on the WHO recommendation [25].
Diabetes measures
Two indicators of diabetes were used: glycated haemoglobin A1c (HbA1c), and 2-hour oral
glucose tolerance test (OGTT). Participants were contacted one day prior to the clinic visit and
instructed to come fasting. Upon arrival and before glucose testing, participants were asked if
they had taken any food except water (i.e. fasted) for at least 8 hours before visiting the clinic.
Those fasting were requested to provide venous blood for HbA1c and glucose measurement
(Hemocue 201 RT, and Hemocue HbA1c 501 respectively; Hemocue AB, Angelholm, Swe-
den). They were then given 82.5g of dextrose monohydrate (equivalent to 75g of anhydrous
glucose) diluted in 250 ml of drinking water to drink within 5 minutes for OGTT, and blood
specimens were collected after 30 minutes and 2 hours. For this analysis we used OGTT data
at 2 hours only. Those who reported not fasting were instructed to come fasting the next day
for testing.
We used WHO guidelines [26] to categorize test results in three levels: normal, prediabetes,
and diabetes mellitus: For OGTT, a 2-hour glucose level 7.8–11.0 mmol/L indicated prediabe-
tes [27], and�11.1 mmol/L indicated diabetes; for HbA1c, prediabetes was 5.7–6.4% and dia-
betes was�6.5%. In addition, we looked at fasting plasma glucose (FPG) as a supplementary
diabetic test for comparison purpose since FPG is widely used in clinical practice. (S1 Table).
HIV and CD4 testing
Venous blood was collected for other tests including HIV status (for participants with
unknown HIV status). HIV testing was done using two rapid antibody tests (SD HIV- 1/2 3.0
SD standard diagnostics Inc, and The Uni-Gold, Trinity Biotech, IDA Business Park, Bray, Co.
Wicklow, Ireland). Discordant samples were tested using Uniform II vironostika-HIV Ag/Ab
Micro-Elisa system (Biomerieuxbv, The Netherlands), and CD4 counts (cells/μL) using
CyflowPartec machine (Partec GmbH, Munster, Germany).
Anthropometry and body composition
Anthropometric measurements were assessed using standardized methods [28]. With partici-
pants barefoot and wearing minimal clothing, body weights were determined to the nearest
0.1 kg using a digital scale (Seca, Germany), and height was measured to the nearest 0.1 cm
using a stadiometer fixed to the clinic wall (Seca, Germany). Mid-upper arm, waist, and hip
circumferences were measured using non-stretchable tape (to 1 mm). Anthropometric mea-
surements were taken in triplicate, and medians were used during analysis. Anthropometric
data collectors were trained to acceptable proficiency before data collection commenced. Body
mass index (BMI) was calculated as weight (kg)/height (m)2 and WHO cut-off values were
used to classify participants as underweight (BMI<18.5kg/m2), normal weight (BMI 18.5–
24.99 kg/m2), and overweight or obese (BMI�25 kg/m2). Waist circumferences�102 cm in
males and�88 cm in females were considered elevated. Participants underwent bioelectrical
impedance analysis (BIA) to estimate fat mass (kg) and fat-free mass (kg) using a body compo-
sition analyser (Tanita BC418, Tokyo, Japan). These body composition parameters were con-
verted to fat mass index (FMI) and fat-free mass index (FFMI) by dividing their values by
height (m)2. Handgrip strength was determined to the nearest 0.1 kg using a digital dynamom-
eter (Takei Scientific Instruments, Japan). Four measurements were taken, with the mean of
the two maximum measurements (one in each hand) reported.
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Ethics statement
Ethical permission to conduct the study was granted by the Medical Research Coordinating
Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania,
the London School of Hygiene and Tropical Medicine and consultative approval from the
National Committee on Health Research Ethics in Denmark. Only patients giving informed
consent were included. Oral and written information in Swahili were provided to all partici-
pants prior to obtaining informed oral and written consent.
Data management and statistics
Data were entered into CSPro and analysed in STATA version 13. Descriptive analysis was
done using histograms for shape distributions and the Shapiro Wilk test for normality for all
continuous variables. Cohort characteristics are presented as medians and interquartile ranges,
means and SDs, or percentages as appropriate. Chi-square tests were used to compare diabetes
and prediabetes between HIV status groups. In addition to HIV status group, other conven-
tional and novel risk factors for diabetes and prediabetes included in analyses were age, sex,
smoking history, alcohol use, physical activity in metabolic equivalents (a computation which
included combination of total time spent in moderate- and vigorous-intensity activity per
week calculated based on WHO recommendation and categorized as<600 or�600 MET-
minutes) [25], grip strength, fruit and vegetable intake, socioeconomic status (SES, calculated
using principal component analysis of variables), BMI, FMI, FFMI, and TB history. SES, grip
strength, FMI and FFMI were grouped in categorical tertiles, age into decades, and CD4
counts were divided into groups of<200, 200–500, and >500 cells/μL.
Univariate multinomial logistic regression models were done for all predictor variables
with the outcomes, prediabetes and diabetes. The associations were presented as relative risk
ratios (RRR) with 95% confidence intervals. Next, we conducted multivariable multinomial
logistic regressions including as independent variables HIV status group, age, sex, FMI and
FFMI plus any variables with an overall effect size of p<0�20 in the univariable analyses for
that diabetes test. To avoid effects of multicollinearity, all predictor variables which qualified
for inclusion in multivariable multinomial regression analysis were assessed for collinearity
measured as Variance Inflation Factor (VIF). Those with VIF <5 were categorized as having
no or moderate collinearity which did not warrant corrective measure and were included in
the final models. BMI, FMI, and FFMI showed a degree of collinearity with VIF>5, so final
models omitted BMI and included only its components, FMI and FFMI. Similarly, the original
study from which participants came was omitted as a variable because of collinearity with TB
history and ART.
Results
Of 1,947 study participants, 1,157 (59%) were female. The mean age was 41 years (SD 12), 655
(34%) were HIV-uninfected, 956 (49%) were HIV-infected and ART-naïve, and 336 (17%)
were HIV-infected on ART (Fig 1). There were 452 (22%) and 206 (29%) participants from the
original TB-NUT and NUSTART cohorts respectively; loss of those originally enrolled in these
previous trials was due to high mortality and loss to follow-up.
The median ART duration for those on ART was 53 months (IQR: 46; 102). Most of the
HIV-uninfected participants were married or cohabiting but about half of the HIV-infected
people were divorced/separated (Table 1). HIV-uninfected participants tended to be more
educated and of higher SES and BMI than HIV-infected participants.
The prevalence of diabetes and prediabetes differed by the two tests and across HIV status
(Table 2). The overall prevalence of diabetes was 13% by HbA1c, and 6% by OGTT. The tests
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identified overlapping but not identical groups of participants (Table 2); in all groups, diabetes
prevalence was higher by HbA1c than by OGTT, but prediabetes was higher by OGTT.
Table 3 shows risk factors for prediabetes and diabetes as assessed by HbA1c. Based on final
multinomial multivariate models as described in the methods, compared with HIV-uninfected
participants, being HIV-infected but not on ART was associated with increased risk of having
diabetes (RRR = 1�95 [95%CI, 1�25–3.03]) and prediabetes (RRR = 2�89 [95%CI, 1�93–4.34]);
being HIV-infected and on ART was associated with increased risk of prediabetes (RRR = 1.80
[95%CI, 1�09–2.94]) but not diabetes. Having CD4 count less than 200 cells/μl at recruitment
was associated with increased risk of diabetes (RRR = 1.79 [95%CI, 1�13–2.83]) but not predia-
betes. Having upper tertile of FFMI was associated with increased risk of diabetes (RRR = 1�66
[95%CI, 1�09–2.52]). FMI was not associated with diabetes or prediabetes. Factors associated
with decreased risk of diabetes were greater than 600 metabolic equivalent-minutes of physical
activity (RRR = 0�57 [95%CI, 0�0.39–0�83]) and upper tertile of grip strength. History of TB
treatment was associated with reduced risk of diabetes and prediabetes in univariate analysis,
but this did not hold up in multivariate analysis.
When measured by OGTT (Table 4), compared to HIV-uninfected participants, being
HIV-infected but not on ART was associated with increased risk of prediabetes (RRR = 1.61
[95%CI, 1�22–2.13]) and of diabetes (RRR = 1.90 [95%CI, 0.96–3.73,]). People who were HIV-
infected and on ART had no differences in multivariable analyses in risk of diabetes or predia-
betes compared to uninfected controls. CD4 count<200 cells/μl was associated with increased
risk of diabetes (RRR = 2.71 [95%CI, 1.36–5.38] but not prediabetes. Adequate physical activ-
ity, upper tertile of grip strength and being a current smoker were associated with decreased
Fig 1. Flow chart showing source and composition of CICADA cohort. Acronyms: HIV+ = HIV-infected, HIV- = HIV-uninfected, HIV+ on
ART = HIV infected on antiretroviral therapy, and HIV+ ART-naïve = HIV not on antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0230723.g001
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Table 1. Demographic and background characteristics of participants1, 2, 3.
Characteristics N HIV STATUS P4
HIV- n = 655 HIV+ ART- n = 956 HIV+ ART+ n = 336
Age, years, mean (SD) 1947 42.2 (13.2) 38.2 (10.9) 44.9 (10.1) <0.001
18–30 139 (21.2) 256 (26.7) 25 (7.4) <0.001
31–40 183 (27.9) 342 (35.8) 98 (29.2)
41–50 171 (26.1) 223 (23.3) 127 (37.8)
>50 162 (24.7) 135 (14.1) 86 (25.6)
Sex, female 1947 371 (56.6) 577 (60.4) 209 (62.2) 0.17
Marital status 1942
Married/cohabiting 454 (69.3) 434 (45.6) 152 (45.4) <0.001
Widowed/separated /divorced 140 (21.4) 448 (47.1) 172 (51.3)
Single 61 (9.3) 70 (7.3) 11 (3.3)
Education level 1942
No formal education 80 (12.2) 158 (16.6) 81 (24.2) <0.001
Primary education 426 (65.0) 676 (71.0) 224 (66.8)
Secondary/tertiary college 149 (22.8) 118 (12.4) 30 (9.0)
Employment 1942
Salaried 62 (9.5) 165 (17.3) 41 (12.3) <0.001
Self-employed 483 (73.7) 654 (68.7) 256 (76.4)
Unemployed/housewife 110 (16.8) 133 (14.0) 38 (11.3)
Ever treated for TB 1945 526 (80.3) 897 (94.0) 147 (43.7) <0.001
Socioeconomic status 1942
Lower 167 (25.5) 316 (33.2) 165 (49.3) <0.001
Middle 220 (33.6) 328 (34.5) 99 (29.5)
Upper 268 (40.9) 308 (32.3) 71 (21.2)
Fruit and vegetable consumption (servings/day) 1929 <0.001
0 74 (11.4) 148 (15.7) 17 (5.1)
1–2 368 (56.4) 494 (52.4) 152 (45.4)
3–4 135 (20.7) 196 (20.8) 89 (26.6)
� 5 75 (11.5) 104 (11.0) 77 (22.9)
Physical activity (MET-minutes per week)5 1941
< 600 82 (12.6) 137 (14.4) 51 (15.2) 0.44
�600 571 (87.4) 815 (85.6) 285 (84.8)
Smoking
Never 507 (77.5) 727 (76.4) 240 (71.4) <0.001
Ex-smoker 89 (13.6) 116 (12.2) 81 (24.1)
Current smoker 58 (8.9) 109 (11.4) 15 (4.5)
Never taken alcohol 1942 212 (32.4) 248 (26.1) 93 (16.8) 0.02
Grip strength (kg), mean (SD)6 1945 30.3 (8.7) 26.5 (8.4) 28.3 (8.4) 0.54
Body mass index (kg/m2), mean (SD) 1946 23.6 (4.9) 21.1 (4.1) 20.7 (3.7) <0.001
<18.5 kg/m2 86 (13.1) 254 (26.6) 86 (25.6) <0.001
18.5–25.0 kg/m2 351 (53.6) 565 (59.2) 214 (63.7)
> 25.0 kg/m2 218 (33.3) 136 (14.2) 36 (10.7)
Waist circumference (cm), mean (SD)7 1946 83.5 (12.6) 77.0 (9.5) 78.6 (9.9) <0.001
Normal 500 (76.3) 863 (90.4) 290 (86.3) <0.001
Increased 155 (23.7) 92 (9.6) 46 (13.7)
Fat mass index (kg/m2), mean (SD)8 1900 6.3 (3.9) 4.6 (3.4) 4.5 (3.1) <0.001
Lower tertile 153 (23.6) 360 (39.1) 121 (36.7) <0.001
(Continued)
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Table 1. (Continued)
Characteristics N HIV STATUS P4
HIV- n = 655 HIV+ ART- n = 956 HIV+ ART+ n = 336
Middle tertile 202 (31.1) 299 (32.5) 132 (40.0)
Upper tertile 294 (45.3) 262 (28.5) 77 (23.3)
Fat-free mass index, (kg/m2) mean (SD)9 1900 17.1 (1.9) 16.3 (1.8) 16.0 (1.6) 0.002
Lower tertile 143 (22.0) 345 (37.5) 146 (44.2) <0.001
Middle tertile 216 (33.3) 301 (32.7) 116 (35.2)
Upper tertile 290 (44.7) 275 (29.8) 68 (20.6)
CD4 count (cell/μL), median (IQR) 1944 678 (542; 831) 224 (93; 401) 366 (242; 488) 0.01
More than 500 534 (81.8) 152 (15.9) 79 (23.5) <0.001
200–500 113 (17.3) 366 (38.3) 204 (60.7)
Less than 200 6 (0.9) 437 (45.7) 53 (15.8)
Duration on ART (Months), median (IQR) 333 0 0 53 (47; 102)
Cohort recruited 1947
TB-NUT cohort 286 (43.7) 37 (3.9) 129 (38.4) <0.001
NUSTART cohort 0 (0.0) 5 (0.5) 201 (59.8)
New cohort 369 (56.3) 914 (95.6) 6 (1.8)
1Data are number (%) unless specifically indicated as mean (SD) or median (IQR);
2 Data do not sum to 1947 due to missing values;
3 HIV- = HIV uninfected, HIV+ ART- = HIV infected not on ART, HIV+ART+ = HIV on ART
4X2– test used for categorical variables, A one-way analysis of variance for parametric variables and Kruskal Wallis for non-parametric variables
5Computation included combination of total time spent in moderate and in vigorous physical activity per week
6Grip strengths tertile cut offs defined as; 0.0–23.6 for lower; 23.7–30.6 for middle and 30.7–59.6 for upper
7Waist circumference increase is defined as�88 cm for women and� 102 cm for men
8Fat mass index tertile cut offs defined as; 0.19–3.03 for lower; 3.04–5.76 for middle and 5.77–22.00 for upper
9Fat-free mass index tertile cut offs defined as; 11.12–15.61 for lower; 15.62–17.20 for middle and 17.21–24.24 for upper
https://doi.org/10.1371/journal.pone.0230723.t001
Table 2. Prevalence of prediabetes and diabetes as defined by oral glucose tolerance test (OGTT) and glycated haemoglobin A1c (HbA1c)1, 2, 3.
Characteristics N HIV- HIV+, ART- HIV+, ART+ P
HbA1c (%) 1944
Normal (�6) 536 (81.8) 567 (59.4) 259 (77.3) <0.001
Prediabetes (6.0–6.4) 58 (8.9) 218 (22.9) 50 (14.9)
Diabetes (�6.5) 61 (9.3) 169 (17.7) 26 (7.8)
OGTT (mmol/L) 1941
Normal (�7.7) 378 (58.1) 418 (43.8) 173 (51.6) <0.001
Prediabetes (7.8–11.0) 247 (37.9) 450 (47.1) 151 (45.1)
Diabetes (�11.1) 26 (4.0) 87 (9.1) 11 (3.3)
HbA1c (%) and OGTT (mmol/L) overlap 1940
No diabetes or prediabetes by any measure 581 (89.3) 731 (76.6) 301 (89.8) <0.001
Diabetes by HbA1c only 44 (6.7) 136 (14.3) 23 (6.9)
Diabetes by OGTT only 11 (1.7) 54 (5.6) 8 (2.4)
Diabetes by both measures 15 (2.3) 33 (3.5) 3 (0.9)
1Data are number (%)
2For each test, data do not sum to 1947 due to missing values
3HIV- = HIV uninfected, HIV+ ART- = HIV infected not on ART, HIV+ART+ = HIV infected on ART, X2– test used to test relationships between categorical variables
https://doi.org/10.1371/journal.pone.0230723.t002
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Table 3. Multinomial analysis of factors associated with prediabetes and diabetes assessed by glycated haemoglobin A1c (HbA1c), taking "no diabetes" as the refer-
ence category.
Univariate1 Multivariate1
Prediabetes2 (N = 326) P Diabetes2 (N = 256) P Prediabetes2 (N = 326) P Diabetes2 (N = 256) P3
RRR, (95% CI) RRR, (95% CI) RRR, (95% CI) RRR (95% CI)
Age (years)
18–30 1 0.01 1 0.89 1 0.50 1 0.36
31–40 1.05 (0.76; 1.44) 0.96 (0.65; 1.40) 1.05 (0.75; 1.47) 0.97 (0.64; 1.45)
41–50 0.79 (0.55; 1.10) 1.04 (0.71; 1.54) 0.89 (0.61; 1.29) 1.19 (0.78; 1.81)
>50 0.60 (0.40; 0.89) 1.11 (0.74; 1.67) 0.77 (0.49; 1.21) 1.37 (0.87; 2.18)
Sex
Female 1 <0.001 1 0.37 1 0.007 1 0.07
Male 0.50 (0.38; 0.65) 0.88 (0.67; 1.16) 0.51 (0.31; 0.83) 0.62 (0.37; 1.03)
HIV status
Negative 1 <0.001 1 <0.001 1 <0.001 1 0.002
Positive not on ART 3.55 (2.59; 4.86) 2.61 (1.91; 3.59) 2.89 (1.93; 4.34) 1.95 (1.25; 3.03)
Positive on ART 1.78 (1.18; 2.67) 0.88 (0.54; 1.43) 1.80 (1.09; 2.94) 0.99 (0.55; 1.76)
TB treatment history
Never treated for TB 1 0.004 <0.001 1 0.86 1 0.67
Treated for TB 0.61 (0.44; 0.86) 0.42 (0.27; 0.64) 0.96 (0.65; 1.43) 0.64 (0.39; 1.03)
Fruit and vegetable consumption (servings/day)
0 1 0.56 1 0.69 - -
1–2 0.81 (0.56; 1.18) 0.95 (0.63; 1.44) - -
3–4 0.94 (0.62; 1.43) 0.82 (0.51; 1.34) - -
� 5 0.98 (0.62; 1.57) 1.09 (0.65; 1.83) - -
CD4 count (cell/μL)
More than 500 1 <0.001 1 <0.001 1 0.007 1 0.001
200–500 1.29 (0.96; 1.75) 1.02 (0.72; 1.43) 0.84 (0.58; 1.20) 0.80 (0.53; 1.04)
Less than 200 2.84 (2.09; 3.84) 2.99 (2.17; 4.14) 1.42 (0.95; 2.13) 1.79 (1.13; 2.83)
BMI (kg/m2)
18.5–25 1 <0.035 1 0.005 - -
<18.5 1.38 (1.03; 1.86) 1.66 (1.20; 2.28) - -
> 25.0 1.37 (1.01; 1.87) 1.39 (0.98; 1.95) - -
Grip strength4
Lower tertile 1 <0.001 1 0.003 1 0.66 1 0.08
Middle tertile 0.71 (0.53; 0.94) 0.63 (0.46; 0.87) 0.89 (0.65; 1.21) 0.73 (0.51; 1.04)
Upper tertile 0.42 (0.31; 0.58) 0.52 (0.38; 0.73) 0.83 (0.54; 1.28) 0.61 (0.38; 0.97)
Waist circumference (cm)5
Normal 1 0.21 1 0.21 - - -
Increased 1.23 (0.89; 1.71) 1.26 (0.88; 1.79) - - -
Fat mass index (kg/m2)6
Lower tertile 1 0.62 1 0.25 1 0.53 1 0.17
Middle tertile 1.07 (0.78; 1.45) 0.76 (0.54; 1.06) 0.82 (0.57; 1.69) 0.69 (0.47; 1.03)
Upper tertile 1.16 (0.86; 1.57) 0.83 (0.60; 1.16) 0.90 (0.60; 1.36) 0.72 (0.46; 1.14)
Fat free mass index (kg/m2)7
Lower tertile 1 0.004 1 0.93 1 0.96 1 0.06
Middle tertile 0.79 (0.59; 1.06) 0.96 (0.68; 1.34) 1.02 (0.74; 1.41) 1.33 (0.92; 1.92)
Upper tertile 0.59 (0.43; 0.80) 1.01 (0.73; 1.41) 1.06 (0.72; 1.55) 1.66 (1.09; 2.52)
Physical activity (MET-min)8
(Continued)
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risk of diabetes or prediabetes, while FMI and FFMI were not associated with diabetes or pre-
diabetes. Older age and being male increased risk of diabetes.
Discussion
We report a high burden of diabetes among Tanzanian adults, with an increased risk among
HIV-infected individuals. This contrasts with recent systematic reviews suggesting that in the
African setting, HIV and ART are not associated with diabetes, although the reviews’ findings
may be limited by heterogeneity and small numbers of studies [7, 29]. Although diabetes prev-
alence varied with the different diagnostic tests, HIV positivity, especially without ART, was
generally associated with increased risk of diabetes or prediabetes. For both OGTT and HbA1c
tests, similar other risk factors, e.g. low CD4 count and low physical activity, were associated
with increased risk of diabetes. The high prevalence estimates for diabetes found in our study
are similar to those reported previously among Tanzanians with HIV infection [30, 31]. The
observed variations in diabetes prevalence measured by the two tests have been reported else-
where, and are likely related to the different components of the glucose metabolic pathway
measured by the tests [32, 33].
Table 3. (Continued)
Univariate1 Multivariate1
Prediabetes2 (N = 326) P Diabetes2 (N = 256) P Prediabetes2 (N = 326) P Diabetes2 (N = 256) P3
RRR, (95% CI) RRR, (95% CI) RRR, (95% CI) RRR (95% CI)
< 600 1 0.89 1 0.005 1 0.22 1 0.004
�600 0.97 (0.68; 1.39) 0.61 (0.43; 0.86) 0.78 (0.52; 1.16) 0.57 (0.39; 0.83)
History of alcohol drinking
No 1 0.87 1 0.21 - -
Yes 0.98 (0.75; 1.28) 1.03 (0.76; 1.39) - -
Smoking history
Never 1 <0.004 1 0.91 1 0.34 1 0.39
Ex-smoker 0.58 (0.39; 0.85) 1.05 (0.72; 1.51) 0.84 (0.52; 1.35) 1.31 (0.84; 2.04)
Current smoker 0.58 (0.36; 0.94) 1.09 (0.70; 1.69) 0.65 (0.36; 1.17) 0.92 (0.53; 1.61)
ART regimen9
AZT backbone 1 0.16 1 0.56 - - -
ABC and other backbone 1.05 (0.28; 3.89) 1.26 (0.26; 6.18) - - -
TDF backbone 1.83 (0.96; 3.47) 1.59 (0.68; 3.72) - - -
Cohort recruited
TB -NUT cohort 1 <0.001 1 <0.001 - - -
NUSTART cohort 1.75 (1.03; 2.98) 1.14 (0.62; 2.09) - - -
New cohort 3.37 (2.33; 4.88) 2.69 (1.84; 3.93) - - -
1 Multivariate analysis included age, sex, fat mass index and fat free mass index; and all variables with overall P value <0.2 in the in univariate analyses; body mass index
and cohort recruited were not included in multivariable analysis because of collinearity with other included variables.
2Cutoff point for defining diabetes and prediabetes based on WHO criteria; RRR = Relative risk ratio;
3 Bolded estimates within variables categories has P value <0.05
4Grip strengths tertile cut offs defined as; 0.0–23.6 for lower; 23.7–30.6 for middle and 30.7–59.6 for upper
5Waist circumference increase is defined as�88 cm for women and� 102 cm for men
6Fat mass index tertile cut offs defined as; 0.19–3.03 for lower; 3.04–5.76 for middle and 5.77–22.00 for upper
7Fat-free mass index tertile cut offs defined as; 11.12–15.61 for lower; 15.62–17.20 for middle and 17.21–24.24 for upper
8Computation included combination of total time spent in moderate and in vigorous physical activity per week
9AZT- azidothymidine, ABC-Abacavir and TDF-Tenofovir containing regimen
https://doi.org/10.1371/journal.pone.0230723.t003
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Table 4. Multinomial analysis of factors associated with prediabetes and diabetes assessed by oral glucose tolerance test (OGTT), taking "no diabetes" as the refer-
ence category.
Univariate1 Multivariate1
Prediabetes2 (N = 326) P Diabetes2 (N = 256) P Prediabetes2 (N = 326) P Diabetes2 (N = 256) P3
RRR, (95% CI) RRR, (95% CI) RRR, (95% CI) RRR (95% CI)
Age (years)
18–30 1 0.03 1 <0.001 1 0.055 1 0.002
31–40 1.15 (0.89; 1.48) 1.51 (0.79; 2.85) 1.18 (0.90; 1.54) 1.44 (0.73; 2.85)
41–50 1.28 (0.97; 1.66) 2.24 (1.19; 4.21) 1.36 (1.02; 1.81) 2.36 (1.19; 4.64)
>50 1.53 (1.14; 2.04) 4.08 (2.19;7.61) 1.52 (1.10; 1.11) 4.01 (1.99; 8.04)
Sex
Female 1 0.005 1 0.001 1 0.62 1 0.03
Male 1.10 (0.91; 1.32) 1.94 (1.33; 2.83) 1.09 (0.79; 1.55) 2.12 (1.07; 4.17)
HIV status
Negative 1 <0.001 1 <0.001 1 0.002 1 0.004
Positive not on ART 1.65 (1.34; 2.02) 3.03 (1.91; 4.79) 1.61 (1.22; 2.13) 1.90 (0.96; 3.73)
Positive on ART 1.33 (1.02; 1.75) 0.92 (0.44; 1.91) 1.19 (0.87; 1.65) 0.58 (0.24; 1.39)
TB treatment history
Never treated for TB 1 0.80 1 0.28 - -
Treated for TB 1.03 (0.82; 1.30) 0.75 (0.45; 1.26) - -
Fruit and vegetable consumption (servings/day)
0 1 0.07 1 0.61
1–2 1.34 (0.99; 1.80) 1.21 (0.66; 2.22) - -
3–4 1.40 (1.00; 1.95) 1.29 (0.65; 2.55) - -
� 5 1.63 (1.13; 2.37) 1.62 (0.78; 3.37) - -
CD4 count (cell/μL)
More than 500 1 <0.001 1 <0.001 1 0.33 1 0.004
200–500 1.25 (1.01; 1.54) 1.08 (0.63; 1.83) 1.04 (0.80; 1.35) 0.98 (0.51; 1.89)
Less than 200 1.69 (1.33; 2.14) 4.35 (2.75; 6.83) 1.24 (0.90; 1.71) 2.71 (1.36; 5.38)
BMI (kg/m2)
18.5–25 1 0.13 1 0.004 - -
<18.5 1.24 (0.98; 1.57) 2.39 (1.55;3.67) - -
> 25.0 1.17 (0.92; 1.48) 1.41 (0.86;2.32) - -
Grip strength4
Lower tertile 1 0.27 1 0.08 1 0.64 1 0.02
Middle tertile 0.83 (0.66; 1.04) 0.69 (0.44; 1.08) 0.89 (0.70; 1.14) 0.71 (0.42; 1.19)
Upper tertile 0.88 (0.70; 1.10) 0.61 (0.38; 0.97) 0.88 (0.64; 1.21) 0.39 (0.20; 0.76)
Waist circumference (cm)5
Normal 1 0.68 1 0.34 - -
Increased 1.05 (0.82; 1.36) 0.85 (0.48; 1.47) - -
Fat mass index (kg/m2)6
Lower tertile 1 0.72 1 0.009 1 0.78 1 0.51
Middle tertile 0.92 (0.73; 1.16) 0.59 (0.37; 0.92) 0.93 (0.72; 1.21) 0.74 (0.43; 1.25)
Upper tertile 0.92 (0.73; 1.16) 0.51 (0.32; 0.82) 1.01 (0.74; 1.37) 0.88 (0.46; 1.68)
Fat free mass index (kg/m2)7
Lower tertile 1 0.67 1 0.05 1 0.74 1 0.21
Middle tertile 0.91 (0.73; 1.15) 0.56 (0.34; 0.91) 1.02 (0.79; 1.30) 0.71 (0.41; 1.20)
Upper tertile 1.03 (0.79; 1.26) 0.91 (0.59; 1.42) 1.11 (0.84; 1.45) 1.11 (0.63; 1.97)
Physical activity (MET-min)8
(Continued)
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Diabetes, particularly Type 2, results from insulin resistance and failure of beta-cell func-
tion, with the former preceding the latter [34]. Patients with prediabetes (impaired fasting
glucose (IFG) and impaired glucose tolerance (IGT)), a transitional state of dysglycaemia pre-
ceding diabetes diagnosis by OGTT, have different degrees of both defects (beta-cell function
failure and insulin resistance) which may occur together [35]. However, patients with IGT
diagnosed by OGTT are more likely to have a defect in skeletal muscle insulin resistance (char-
acterized by inability of skeletal muscle to utilize glucose). Unlike OGTT, Hb1Ac measures
average glucose levels in the past 12 weeks and therefore is likely to diagnose patients with
both marked hepatic and skeletal insulin resistance [36, 37].
Our finding that HIV infection is a risk factor for diabetes diagnosed by HbA1c and OGTT
in adults not on ART may indicate that before starting ART, HIV-infected patients have high
levels of muscle insulin resistance, probably resulting from inflammation and immune activa-
tion [11]. Although diabetes or prediabetes risk persists during ART, our observation that it is
only apparent by HbA1c suggests that during ART, hepatic insulin resistance may be a driver
of hyperglycemia, possibly due to liver fat accumulation or other adverse effects of ART drugs
[38, 39]. Future work should focus on understanding the relative contributions of beta-cell
Table 4. (Continued)
Univariate1 Multivariate1
Prediabetes2 (N = 326) P Diabetes2 (N = 256) P Prediabetes2 (N = 326) P Diabetes2 (N = 256) P3
RRR, (95% CI) RRR, (95% CI) RRR, (95% CI) RRR (95% CI)
< 600 1 <0.001 1 <0.001 1 <0.001 1 0.001
�600 0.49 (0.37; 0.66) 0.26 (0.26; 0.58) 0.53 (0.38; 0.71) 0.43 (0.19; 0.95)
History of alcohol drinking
No 1 0.97 1 0.26 - -
Yes 1.00 (0.82; 1.23) 0.79 (0.53; 1.18) - -
Smoking history
Never 1 0.19 1 0.045 1 0.06 1 0.08
Ex-smoker 1.14 (0.87; 1.49) 1.79 (1.12; 2.87) 0.95 (0.69; 1.29) 1.06 (0.59; 1.89)
Current smoker 0.79 (0.58; 1.10) 0.94 (0.48; 1.82) 0.63 (0.43; 0.93) 0.43 (0.19; 0.94)
ART regimen9
AZT backbone 1 0.19 1 0.43 - -
ABC and other backbone 1.32 (0.55; 3.29) 2.93 (0.51; 16.83) - -
TDF backbone 1.52 (0.96; 2.40) 0.96 (0.24; 3.72) - -
Cohort recruited
TB -NUT cohort 1 0.69 1 0.10 - -
NUSTART cohort 1.12 (0.80; 1.57) 0.52 (0.21; 1.29) - -
New cohort 0.98 (0.78; 1.23) 1.24 (0.78; 1.97) - -
1 Multivariate analysis included age, sex, fat mass index and fat free mass index; and all variables with overall P value <0.2 in the in univariate analyses; body mass index
and cohort recruited were not included in multivariable analysis because of collinearity with other included variables. 2Cutoff point for defining diabetes and
prediabetes based on WHO criteria; RRR = Relative risk ratio;
3 Bolded estimates within variables categories has P value <0.05
4Grip strengths tertile cut offs defined as; 0.0–23.6 for Lower; 23.7–30.6 for Middle and 30.7–59.6 for Upper
5Waist circumference increase is defined as�88 cm for women and� 102 cm for men
6Fat mass index tertile cut offs defined as; 0.19–3.03 for Lower; 3.04–5.76 for Middle and 5.77–22.00 for Upper
7Fat-free mass index tertile cut offs defined as; 11.12–15.61 for Lower; 15.62–17.20 for Middle and 17.21–24.24 for Upper
8Computation included combination of total time spent in moderate and in vigorous physical activity per week
9AZT- azidothymidine, ABC-Abacavir and TDF-Tenofovir containing regimen
https://doi.org/10.1371/journal.pone.0230723.t004
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deficiency and insulin resistance in the evolution of diabetes in HIV patients and how this
affects the diagnostic characteristics of HbA1c and OGTT.
In our analysis, ageing, being male, and CD4 counts<200 cells/μL were significantly associ-
ated with diabetes by one or both tests. Ageing is well documented as a risk factor for diabetes,
and male sex has been reported as a risk factor for diabetes among HIV-infected patients [40],
although there is no clear explanation for this. In contrast to other studies showing increased
diabetes risk with increased fat, especially central fat, we found virtually no associations of
BMI, FMI, FFMI or waist circumference with diabetes risk. This could be because in general
the population had normal or low BMI, with only 120 (6%) of the participants having BMI
>30; virtually all of these were women and most were HIV-negative, so in multivariable analy-
ses including sex and HIV status, BMI would have made limited additional contribution. We
suspect that the increased risk of diabetes by HbA1c in the highest FFMI tertile may be a spuri-
ous association, especially since there was no evidence of increased risk in the univariable
analyses.
The association of CD4 count with diabetes suggests that immune impairment resulting
from HIV infection may magnify the risk of glucose dysregulation. Low CD4 count has previ-
ously been associated with diabetes in HIV-infected individuals [41] and helps explain the
links between infectious and non-communicable diseases. Physical activity greater than 600
metabolic equivalents per week and an upper tertile of handgrip strength in our study were
associated with reduced risk of diabetes. Physical activity tends to reduce fat storage and sys-
temic inflammation and modulates metabolic balance [42]. Grip strength is a measure of mus-
cular strength and good health in general, which may help reduce NCDs including diabetes.
Individuals who are more active are less likely to have high blood pressure, type 2 diabetes,
and metabolic syndrome [43]. However, given the cross-sectional nature of our study, it is pos-
sible that higher activity level merely reflects healthier people with no diabetes and better HIV
control, which enable them to participate in work or leisure activities. An intervention trial
would be needed to determine whether encouraging HIV-infected African adults to increase
physical activity will reduce chances of developing diabetes.
Our finding that self-reported current smoking was associated with reduced risk of diabetes
as assessed by OGTT is inconsistent with other studies reported elsewhere, where smoking
was associated with diabetes [44]. Smoking may be a SES factor associated with being better
off, but our finding may be spurious and related to a short time exposure between smoking
initiation and being enrolled in our study, or bias with self-reporting, or that the majority who
responded as current smokers were healthier. However, in the general population, studies
have shown no differences in smoking behavior among those with and without diabetes [45].
A strength of our study was that it had a relatively large sample size to examine associations
between risk factors and diabetes. In addition, unlike previous reports which used one method
of diabetes diagnosis, we used two methods. This enabled us to examine associations among
patients who may have different diabetes profiles, thus increasing our understanding of the
roles of hypothesized risk factors in diabetes.
A limitation of our study is that patients on ART came from our previous TB-NUT and
NUSTART cohorts which had high mortality, and it is likely that the observed risk represents
diabetes risk among survivors. Furthermore, NUSTART recruited patients starting ART when
malnourished (BMI<18.5 kg/m2), and our previous follow-up of the NUSTART participants
[31] as well as other studies from Africa [46, 47] have suggested that malnutrition could lead to
diabetes after nutritional recovery. Therefore, in our study it is hard to disentangle potential
effects of ART and prior malnutrition on diabetes risk. Further longitudinal follow-up of HIV-
infected persons newly enrolled in CICADA will be informative, as they will likely have lower
HIV-related mortality risk because they started ART when healthier in comparison to those
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from our previous cohorts who were recruited when only those with low CD4 counts were
offered ART. Higher survival rates in current cohorts treated for HIV when healthier, i.e.,
before becoming severely immunocompromised and developing AIDS, may result in different
diabetes-related outcomes. Finally, this was a cross-sectional study, and we cannot conclude
whether HIV and/or ART leads to diabetes.
Conclusion
We found the prevalence of prediabetes or diabetes among HIV-infected persons to be higher
than in HIV-uninfected persons, particularly for those not on ART. The relative merits of the
different measures of prediabetes and diabetes among HIV-infected persons may require
monitoring of end-organ impacts of diabetes over time. High-level physical activity was
strongly associated with reduced risk of diabetes; if a causal association is confirmed by other
studies, promoting physical activity among HIV-infected Africans may be important in reduc-
ing diabetes risk. Health systems should consider integrating diabetes screening and treatment
in HIV care systems to optimize the care of HIV patients and improve their health outcomes.
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